Cimetropium

DB09271

small molecule experimental investigational

Deskripsi

Cimetropium is a semi-synthetic belladonna alkaloid and derivative of scopolamine. It is a potent antimuscarinic and an effective antispasmodic drug. It is also endowed of a direct myolitic action which partially accounts for its antispasmodic activity. It has never been approved for use in the U.S. or Canada.

Struktur Molekul 2D

Berat 358.457
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

135 Data
Nicotine Nicotine may decrease the anticholinergic activities of Cimetropium.
Cevimeline Cevimeline may decrease the anticholinergic activities of Cimetropium.
Carbamoylcholine Carbamoylcholine may decrease the anticholinergic activities of Cimetropium.
Bethanechol Bethanechol may decrease the anticholinergic activities of Cimetropium.
Pilocarpine Pilocarpine may decrease the anticholinergic activities of Cimetropium.
Varenicline Varenicline may decrease the anticholinergic activities of Cimetropium.
Acetylcholine Acetylcholine may decrease the anticholinergic activities of Cimetropium.
Arecoline Arecoline may decrease the anticholinergic activities of Cimetropium.
Lobeline Lobeline may decrease the anticholinergic activities of Cimetropium.
NGX267 NGX267 may decrease the anticholinergic activities of Cimetropium.
GTS-21 GTS-21 may decrease the anticholinergic activities of Cimetropium.
Methacholine Methacholine may decrease the anticholinergic activities of Cimetropium.
Epibatidine Epibatidine may decrease the anticholinergic activities of Cimetropium.
Xanomeline Xanomeline may decrease the anticholinergic activities of Cimetropium.
Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Cimetropium.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Cimetropium.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Cimetropium.
Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Cimetropium.
Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cimetropium.
Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Cimetropium.
Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Cimetropium.
Ipratropium The risk or severity of adverse effects can be increased when Ipratropium is combined with Cimetropium.
Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Cimetropium.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Cimetropium.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Cimetropium.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Cimetropium.
Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Cimetropium.
Doxylamine The risk or severity of adverse effects can be increased when Doxylamine is combined with Cimetropium.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Cimetropium.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Cimetropium.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Cimetropium.
Profenamine The risk or severity of adverse effects can be increased when Profenamine is combined with Cimetropium.
Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Cimetropium.
Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Cimetropium.
Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Cimetropium.
Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Cimetropium.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Cimetropium.
Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cimetropium.
Gallamine triethiodide The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Cimetropium.
Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Cimetropium.
Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Cimetropium.
Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Cimetropium.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Cimetropium.
Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Cimetropium.
Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Cimetropium.
Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Cimetropium.
Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Cimetropium.
Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Cimetropium.
Paroxetine The risk or severity of adverse effects can be increased when Paroxetine is combined with Cimetropium.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Cimetropium.
Rocuronium The risk or severity of adverse effects can be increased when Rocuronium is combined with Cimetropium.
Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Cimetropium.
Benzquinamide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Cimetropium.
Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Cimetropium.
Propiomazine The risk or severity of adverse effects can be increased when Propiomazine is combined with Cimetropium.
Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Cimetropium.
Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Cimetropium.
Biperiden The risk or severity of adverse effects can be increased when Biperiden is combined with Cimetropium.
Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Cimetropium.
Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Cimetropium.
Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Cimetropium.
Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Cimetropium.
Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Cimetropium.
Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Cimetropium.
Cycrimine The risk or severity of adverse effects can be increased when Cycrimine is combined with Cimetropium.
Glycopyrronium The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Cimetropium.
Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Cimetropium.
Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Cimetropium.
Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Cimetropium.
Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cimetropium.
Doxacurium The risk or severity of adverse effects can be increased when Doxacurium is combined with Cimetropium.
Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Cimetropium.
Flavoxate The risk or severity of adverse effects can be increased when Flavoxate is combined with Cimetropium.
Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Cimetropium.
Orphenadrine The risk or severity of adverse effects can be increased when Orphenadrine is combined with Cimetropium.
Escitalopram The risk or severity of adverse effects can be increased when Escitalopram is combined with Cimetropium.
Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Cimetropium.
Mivacurium The risk or severity of adverse effects can be increased when Mivacurium is combined with Cimetropium.
Diphenidol The risk or severity of adverse effects can be increased when Diphenidol is combined with Cimetropium.
Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cimetropium.
Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cimetropium.
Metocurine The risk or severity of adverse effects can be increased when Metocurine is combined with Cimetropium.
Pancuronium The risk or severity of adverse effects can be increased when Pancuronium is combined with Cimetropium.
Pipecuronium The risk or severity of adverse effects can be increased when Pipecuronium is combined with Cimetropium.
Methotrimeprazine The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Cimetropium.
Tiotropium The risk or severity of adverse effects can be increased when Tiotropium is combined with Cimetropium.
Solifenacin The risk or severity of adverse effects can be increased when Solifenacin is combined with Cimetropium.
Isopropamide The risk or severity of adverse effects can be increased when Isopropamide is combined with Cimetropium.
Rapacuronium The risk or severity of adverse effects can be increased when Rapacuronium is combined with Cimetropium.
Mepenzolate The risk or severity of adverse effects can be increased when Mepenzolate is combined with Cimetropium.
Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Cimetropium.
Fesoterodine The risk or severity of adverse effects can be increased when Fesoterodine is combined with Cimetropium.
Hexocyclium The risk or severity of adverse effects can be increased when Hexocyclium is combined with Cimetropium.
Dimetindene The risk or severity of adverse effects can be increased when Dimetindene is combined with Cimetropium.
Aclidinium The risk or severity of adverse effects can be increased when Aclidinium is combined with Cimetropium.
Dexetimide The risk or severity of adverse effects can be increased when Dexetimide is combined with Cimetropium.
Benactyzine The risk or severity of adverse effects can be increased when Benactyzine is combined with Cimetropium.
Umeclidinium The risk or severity of adverse effects can be increased when Umeclidinium is combined with Cimetropium.
Trimebutine The risk or severity of adverse effects can be increased when Trimebutine is combined with Cimetropium.
Dosulepin The risk or severity of adverse effects can be increased when Dosulepin is combined with Cimetropium.

Target Protein

Muscarinic acetylcholine receptor M5 CHRM5

Referensi & Sumber

Artikel (PubMed)
  • PMID: 3912339
    Scarpignato C, Bianchi Porro G: Cimetropium bromide, a new antispasmodic compound: pharmacology and therapeutic perspectives. Int J Clin Pharmacol Res. 1985;5(6):467-77.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul